Leap Therapeutics Inc. (NASDAQ:LPTX) shares, rose in value on Thursday, 05/25/23, with the stock price down by -3.68% to the previous day’s close as strong demand from buyers drove the stock to $0.76.
Actively observing the price movement in the last trading, the stock closed the session at $0.79, falling within a range of $0.7205 and $0.85. Referring to stock’s 52-week performance, its high was $1.86, and the low was $0.27. On the whole, LPTX has fluctuated by 109.42% over the past month.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
With the market capitalization of Leap Therapeutics Inc. currently standing at about $89.33 million, investors are eagerly awaiting this quarter’s results, scheduled for Aug 10, 2023 – Aug 14, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.09, which is expected to increase to -$0.05 for fiscal year -$0.49 and then to about -$0.33 by fiscal year 2024. Data indicates that the EPS growth is expected to be -2.10% in 2024, while the next year’s EPS growth is forecast to be 32.70%.
#####
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 2 upward and no downward review(s) in last seven days. We see that LPTX’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Buy.
5 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 3 recommend it as a Buy and 2 called the LPTX stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of LPTX currently trading nearly 51.78% and 85.31% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 77.39, while the 7-day volatility ratio is showing 21.55% which for the 30-day chart, stands at 13.70%. Furthermore, Leap Therapeutics Inc. (LPTX)’s beta value is 0.63, and its average true range (ATR) is 0.08. The company’s stock has been forecasted to trade at an average price of $2.50 over the course of the next 52 weeks, with a low of $2.00 and a high of $3.00. Based on these price targets, the low is -163.16% off current price, whereas the price has to move -294.74% to reach the yearly target high. Additionally, analysts’ median price of $2.50 is likely to be welcomed by investors because it represents a decrease of -228.95% from the current levels.
A comparison of Leap Therapeutics Inc. (LPTX) with its peers suggests the former has fared considerably weaker in the market. LPTX showed an intraday change of -3.68% in last session, and over the past year, it shrunk by -32.14%%. In comparison, Pieris Pharmaceuticals Inc. (PIRS) has moved lower at -7.76% on the day and was down -50.60% over the past 12 months. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.88%. Meanwhile, the Dow Jones Industrial Slipped by -0.11%.
Data on historical trading for Leap Therapeutics Inc. (NASDAQ:LPTX) indicates that the trading volumes over the past 10 days have averaged 2.0 million and over the past 3 months, they’ve averaged 798.50K. According to company’s latest data on outstanding shares, there are 129.34 million shares outstanding.
Nearly 8.28% of Leap Therapeutics Inc.’s shares belong to company insiders and institutional investors own 44.50% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 11.52 million shares as on May 14, 2023, resulting in a short ratio of 30.1. According to the data, the short interest in Leap Therapeutics Inc. (LPTX) stood at 9.65% of shares outstanding as of May 14, 2023; the number of short shares registered in Apr 13, 2023 reached 11.51 million. The stock has risen by 68.89% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LPTX stock heading into the next quarter.
